Bigul

People who are infected should also take vaccine: Bharat Biotech Chairman

People who are infected should also take a vaccine,and India is well prepared regarding the logistics for the vaccine distribution,Bharat BiotechChairman & MD Krishna Ella said on Wednesday. He was speaking in a virtual session on 'Sero surveillance significance in immunogenicity and safety in pre and post vaccination era' organised by industrybody CII. For the peoplewho are infected,shouldthey take a vaccine, "the answeris yes", becausethey may not have a goodT cells response..., Ella said. Talking about the company's efficacy trials of its COVID-19 vaccine, he said that for the efficacy trials the company has taken 24 centres all over the country so that it has tier I ,tierIIand tier III cities to capture the efficacy in a better way. On the distribution of vaccines in India, he said India is well prepared for that and Indian immunisation system is very robust, Ella said. Speaking at the session, Biocon ChairpersonKiran Mazumdar Shaw said, "We have to ensure we have a sense of .
23-12-2020
Bigul

Wistron riots: Karnataka CM BS Yediyurappa urged to fix flaws in labour rules

The labour department should play a very different role in dispute redressal. There should be a proper grievance redressal system to address issues raised by workers early and ensure the workforce does not take law into their hands, Biocon founder Kiran Mazumdar-Shaw told ET.
23-12-2020
Bigul

Biocon Biologics inks pact with CSSC in Tanzania for its Mission 10 cents'

Biotechnology major Biocon on Tuesday said its arm Biocon Biologics has signed a pact with the Christian Social Services Commission (CSSC) in Tanzani
15-12-2020
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Biocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents
15-12-2020
Bigul

Biocon Biologics gets CHMP market authorisation for rapid acting insulin

European Commission decision on the approval is expected early next year'
14-12-2020
Bigul

BIOCON LTD. - 532523 - Disclosure Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations').

Further to our intimation dated November 7, 2020, in relation to execution of a Securities subscription agreement ('SSA') and a shareholders' agreement ('SHA') between Biocon Limited (the 'Company'), Biocon Biologics Limited ('BBL'), existing investors of BBL and Goldman Sachs India AIF Scheme - 1, a scheme setup under Goldman Sachs India Alternative Investment Trust, acting through its investment manager, Goldman Sachs (India) Alternative Investment Management Private Limited (the 'Investor') as applicable, we wish to inform you that the subscription money aggregating to Rs. 1,125 Crores have been received by BBL from the Investor. Consequently, today the Board of BBL has approved the allotment of 1,125 Unlisted, Unsecured, Redeemable, Optionally Convertible Debentures (OCDs) at face value of Rs. 1,00,00,000 (Rupees One Crore) each aggregating to Rs. 1,125 Crores of BBL to the Investor.
09-12-2020
Bigul

Biocon may explore govt research initiatives for Itolizumab

The company already had emergency-use approval for the drug from DCGI
04-12-2020

Roshni Nadar tops Kotak Wealth and Hurun India's list of richest women

Biocon Chairperson Kiran Mazumdar-Shaw is the second-richest woman on the list, with a net worth of 36,600 crore
03-12-2020
Bigul

BIOCON LTD. - 532523 - Reporting Of Violations Under SEBI (Prohibition Of Insider Trading) Regulations, 2015

Please find enclosed herewith the report related to the violation of Company's Code of Conduct for Prevention of Insider Trading by the Designated Person, in the format prescribed by SEBI vide its Circular SEBI/HO/ISD/ISD/CIR/P/2020/135 dated July 23, 2020.
02-12-2020
Next Page
Close

Let's Open Free Demat Account